<DOC>
	<DOCNO>NCT02796183</DOCNO>
	<brief_summary>This study evaluate effect subconjunctivally injected bevacizumab patient diffuse diabetic macular edema .</brief_summary>
	<brief_title>The Efficacy Subconjunctival Bevacizumab Diabetic Macular Edema</brief_title>
	<detailed_description>At baseline , macular thickness eye patient persistant diabetic macular edema measure optical coherence tomography . After 3.75mg bevacizumab inject subconjunctival space eye diabetic macular edema . The measurement macular thickness repeat optical coherence tomography 15th , 30th , 60th day injection . The macular thickness measurement injection compare .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Having diffuse diabetic macular edema persist least 1 month No intravitreal injection last 3 month . No retinal laser photocoagulation last 6 month Not macular disease cause macular edema Having ischemic macula Intravitreal injection last 3 month . Retinal laser photocoagulation last 6 month Have macular disease cause macular edema</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>